ConductScience.org, home

Trial · NCT05935202

Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies

NCT05935202, Phase 2, Not yet recruiting, EuroBloodNet Association

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies. Trials, record NCT05935202. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05935202

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies
NCT number
NCT05935202
Status
Not yet recruiting
Phases
Phase 2
Enrollment
25 participants, estimated
Lead sponsor
EuroBloodNet Association
Conditions
Hereditary Red Blood Cell Disorder (Disorder)
Interventions
Mitapivat sulfate
First posted
2023-07-07
Last updated
2023-12-26

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimarySafety and tolerability of mitapivat in adult patients with erythrocyte membranopathiesUp to 56 weeksFrequency and severity of AEs and laboratory parameters of mitapivat in adult patients with erythrocyte membranopathies
PrimaryPercentage of Participants With AEs and SAEs, Graded by SeverityUp to 56 weeks
The severity of all AEs will be graded by the Investigator according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) on a 5-point severity scale (Grade 1 through Grade 5) where Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening and Grade 5 is fatal.
SecondaryHb response (HR)24 weeksHb response (HR) defined as a ≥1 g/dL increase in Hb concentration from baseline

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMIDListed as
39079928DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05935202

GET https://conductscience.org/api/trials/v1/NCT05935202/registered